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Abstract
Objective
Monogenic diabetes can be misdiagnosed as type 1 or type 2 diabetes in children. The
right diagnosis is crucial for both therapeutic choice and prognosis and influences genetic
counseling. The main objective of this study was to search for monogenic diabetes in Span-
ish pediatric patients suspected of type 1 diabetes with lack of autoimmunity at the onset
of the disease. We also evaluated the extra value of ZnT8A in addition to the classical IAA,
GADA and IA2A autoantibodies to improve the accuracy of type 1 diabetes diagnosis.
Methods
Four hundred Spanish pediatric patients with recent-onset diabetes (mean age 8.9 ± 3.9
years) were analyzed for IAA, GADA, IA2A and ZnT8A pancreatic-autoantibodies and
HLA-DRB1 alleles. Patients without autoimmunity and those with only ZnT8A positive were
screened for 12 monogenic diabetes genes by next generation sequencing.
Results
ZnT8A testing increased the number of autoantibody-positive patients from 373 (93.3%) to
377 (94.3%). An isolated positivity for ZnT8A allowed diagnosing autoimmune diabetes in
14.8% (4/27) of pediatric patients negative for the rest of the antibodies tested. At least 2 of
the 23 patients with no detectable autoimmunity (8%) carried heterozygous pathogenic vari-
ants: one previously reported missense variant in the INS gene (p.Gly32Ser) and one novel
frameshift variant (p.Val264fs) in the HNF1A gene. One variant of uncertain significance
was also found. Carriers of pathogenic variants had HLA-DRB1 risk alleles for autoimmune
diabetes and clinical characteristics compatible with type 1 diabetes except for the absence
of autoimmunity.
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Conclusion
ZnT8A determination improves the diagnosis of autoimmune diabetes in pediatrics. At least
8% of pediatric patients suspected of type 1 diabetes and with undetectable autoimmunity
have monogenic diabetes and can benefit from the correct diagnosis of the disease by
genetic study.
Introduction
Type 1 diabetes (T1D) is an organ-specific autoimmune disorder caused by the destruction of
insulin-producing pancreatic β-cells leading to an absolute insulin deficiency. Although T1D
can be diagnosed at any age, it is one of the most common chronic diseases of childhood.
Peaks in presentation occur between 5–7 years of age and at or near puberty [1]. The presence
of autoantibodies against several pancreatic islet molecules in response to the autoimmune
process is, to date, the best predictive and diagnostic marker for T1D [2]. The autoantibodies
that have been of most interest from a clinical and research perspective are islet-cell cyto-
plasmic autoantibodies (ICA), those against the 65kD isoform of glutamic acid decarboxylase
(GADA), the pancreatic tyrosine phosphatase-like molecule IA-2 (IA-2A) and insulin autoan-
tibodies (IAA). More recently, Zinc transporter 8 protein islet autoantibodies (ZnT8A) have
also been identified [3]. Nevertheless, not all patients with suspected T1D show evidence of
autoimmunity on the basis of the above-mentioned markers [4].
The trigger of the autoimmune process associated with T1D is determined by complex
interactions between several genetic loci (nearly 40 loci described so far) and environmental
factors [1]. Susceptibility to and protection against the development of autoimmune diabetes
are mainly associated with the highly polymorphic sequences of the HLA class II genes on
chromosome 6p21. In Caucasians, HLA haplotypes DRB1�03:01-DQA1�05:01-DQB1�02:01
and DRB1�04-DQA1�03:01-DQB1�03:02 confer the greatest susceptibility, while the
DRB1�15:01-DQA1�01:02-DQB1�06:02 haplotype provides disease protection [5].
Monogenic diabetes (MD) is a clinically and genetically heterogeneous disease that includes
maturity onset diabetes of the young (MODY) and infancy-onset and neonatal diabetes melli-
tus, which are characterized by functional defects of pancreatic β-cells resulting in insulin defi-
ciency and moderate to severe hyperglycemia in early life [6]. It accounts for at least 1–2% of
all cases of diabetes. MODY, the most common type of monogenic diabetes, is an autosomal-
dominant form of non-autoimmune diabetes, typically diagnosed before 25 years of age. More
than 12 different genes have been associated with MODY. Pathogenic variants in GCK and
HNF1A genes account for approximately 80% of all MODY cases followed by HNF4A and
HNF1B genes representing about 10% and 6% respectively, although percentages can differ
dramatically country-to-country due to different recruitment biases. Pathogenic variants in
the remainder of the genes are rare forms of MODY [7].
Given that the clinical features of MD are often non-specific, it is estimated that around
80% of MD cases remain undiagnosed or are misdiagnosed as type 1 or type 2 diabetes [7].
Identification of the correct etiology of diabetes is crucial for clinical management, therapeutic
choice and prognosis, as well as for genetic counseling, when applicable [8].
The main objective of this study was to search, in a cohort of Spanish pediatric patients sus-
pected of T1D, whether a monogenic form of diabetes could be identified in cases with absence
of immunological markers at the onset of the disease. We also aimed to assess the further value
MODY in children diagnosed with type 1 diabetes
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of ZnT8A screening in addition to the classical IAA, GADA and IA2A autoantibodies for the
diagnosis of autoimmune diabetes.
Methods
Patients
We recruited 400 unrelated pediatric patients with recent-onset type 1 diabetes diagnosed
according to the International Society for Pediatric and Adolescent Diabetes (ISPAD) criteria
[9] who were less than a week on insulin replacement therapy. Participants were recruited
from seven referral hospitals in Spain between 2012 and 2017 (mean onset age 8.9 ± 3.9 years,
47.3% female). In all cases HLA-DRB1 alleles and IAA, GADA, IA2A and ZnT8A at diagnosis
were analyzed. It was considered positive autoimmunity to have at least one positive antibody.
Clinical data collected from all patients at diabetes onset included: age, presence of diabetic
ketoacidosis (DKA) according to the ISPAD criteria [10] and family history of diabetes
(Table 1 and S1 Table).
In cases with absence of autoimmunity, more detailed clinical data recorded at diagnosis
and at the last check-up was added. These included: body mass index (BMI) expressed as z-
score for children according to the 2010 Spanish growth charts [12], duration of diabetes
symptoms (polydipsia, polyphagia, polyuria, weight loss and/or blurred vision), analytical data
and insulin dose (Table 2). The study was approved by the corresponding Clinical Research
Ethics Committee and written informed consent was obtained from all subjects and/or their
parents.
Antibody analyses
Pancreatic autoantibodies (IAA, GADA, IA2A and ZnT8A) were determined in serum at diag-
nosis, using previously described standardized radio-assays [13]. IAA were determined using a
competitive fluid-phase radio-assay which uses [125I]-labelled, recombinant human insulin
(PerkinElmer Inc., Waltham, MA, USA) as antigen. GADA, IA2A and ZnT8A were deter-
mined by means of standardized radio-binding assays using in vitro transcribed and translated
[35S]-labelled recombinant human full-length GAD65, IA2ic (amino acids 605–979) and ZnT8
antigen. The ZnT8A assay simultaneously measures autoantibodies against both variants of
Table 1. Characteristics of the population included in the study according to antibody status.
Antibody-positive (n = 377) Antibody-negative (n = 23) p-value
Gender (% female) 48.0 34.8 n.s.a
Age of onset (years) 8.9 ± 3.9 9.6 ± 4.2 n.s.c
1st degree relatives with any DM 17.2 13.0 n.s.b
Presence of DKA 40.8 18.2 0.035a
HLA-DRB1� 0 risk alleles 8.0 8.7 n.s.b
HLA-DRB1� 1 risk allele 42.4 43.5 n.s.a
HLA-DRB1� 2 risk alleles 49.6 47.8 n.s.a
Age is shown as mean ± SD. Rest of data is shown as %. 1st degree relatives: parents and/or siblings (Ab+ n = 372; Ab- n = 23). DKA: Diabetic Ketoacidosis (Ab
+ n = 377; Ab- n = 22). HLA-DRB1 risk alleles are defined based on the report [11]: 0 risk alleles (no DR3 no DR4); 1 risk allele (DR3 or DR4); 2 risk alleles (DR3/3,
DR4/4 or DR3/4).
a Pearson´s chi-square test
b Fisher‘s exact test
c Mann-Whitney U-test
n.s.: no significant differences (p>0.05).
https://doi.org/10.1371/journal.pone.0220634.t001
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the COOH-terminal domain (Arg325/Trp325). Antibody results for GADA, IA2A and ZnT8A
are expressed as a semi-quantitative index calculated using a dilution curve of a positive sam-
ple. All cut-off values were set at the 99th percentile of the control population. Our laboratory
has participated in different islet autoantibody standardization program (IASP) workshops,
the last one in 2018. Specificity was 100% for all four antibody assays and sensitivity was 65%
for IAA, 68% for GADA and 62% for IA2A and ZnT8A.
Genetic analyses
DNA extraction was performed using the QiAamp DNA blood kit (Qiagen, Hilden, NRW,
Germany). DNA quality and quantification was assessed using both NanoDrop ND-1000
(Thermo Fisher Scientific, Waltham, MA, USA) and Qubit 2.0 Fluorometer (Thermo Fisher
Scientific) consistent with the manufacturers’ instructions.
HLA-DRB1 typing. Polymerase chain reaction sequence-specific oligonucleotide
method (PCR-SSO) combined with Luminex technology was carried out using the LABType
RSSOH2B1 (HLA-DRB1-HD) commercial kit (One Lambda, Inc., Canoga Park, CA, USA).
All procedures were performed according to the manufacturers’ instructions. HLA-DRB1 risk
alleles for T1D were defined based on the previous report published by our group [11].
Genetic screening. Genetic testing was performed by next generation sequencing (NGS).
A customized gene panel was designed with the Ion AmpliSeq Designer tool v.4.4.8 (www.
ampliseq.com). The gene panel comprised the 3’ and 5’ UTR regions, promoters, the entire
coding region and exon-intron boundaries (± 50 bp) of 12 known genes related to monogenic
diabetes, including the most frequent genes, such as GCK, HNF1A, HNF4A, HNF1B, INS,
ABCC8, KCNJ11 and the infrequent ones, PDX1, NEUROD1, KLF11, PAX4 and BLK. The tar-
get size was 69,220 bp (272 amplicons from 125 to 375 bp in size) with a theoretical coverage
of 99.13% for the targeted regions.
Libraries were prepared in three pools per patient with the Ion Ampliseq Library kit 2.0
(Thermo Fisher Scientific) according to the manufacturer´s protocol. Sequencing was per-
formed on a PGM Ion Torrent NGS sequencer using the Ion PGM Hi-Q View Sequencing kit
(Thermo Fisher Scientific) and an Ion 316 chip to obtain an average coverage depth of 100
reads per base. Sequence alignment and variant calling were performed using Torrent Suite
Software v.5.0.4. Resulting aligned reads (BAM files) and variant calling files (VCF files) were
then transferred to Ion Reporter Software v.5.10.0 for variant annotation. Variants with low
quality (Phred-like score� 30 associated with a p-value > 0.001) and Minor Allele Frequency
(MAF) > 0.01 in population databases were excluded. The minimal depth per base established
to validate the sequence was 20 reads and any area of interest that did not reach at least 20
reads was sequenced by Sanger (ABI 3130xl Genetic Analyzer, Thermo Fisher Scientific). The
average coverage depth achieved per base and per patient was 508 reads (from 885 to 218 with
a base coverage uniformity of 92%) and 98% of targeted bases were covered by more than 20
reads.
For the validation of this panel we included independent DNA samples from 29 patients
with 64 previously sequenced variants. The analysis showed a sensitivity of 98.5% and a speci-
ficity of 96.5% for point variations and small indels (from 1 to 15 bases).
All variants of interest were confirmed by Sanger sequencing using the Big Dye Terminator
v.3.1 Cycle Sequencing Kit (Thermo Fisher Scientific) and the ABI 3130xl DNA sequencing
system (Thermo Fisher Scientific). When possible, parents and family members of positive
patients were analyzed.
Variant classification. The pathogenicity of rare variants detected (MAF� 0.01) was
determined according to the recommendations of the American College of Medical Genetics
MODY in children diagnosed with type 1 diabetes
PLOS ONE | https://doi.org/10.1371/journal.pone.0220634 July 31, 2019 5 / 14
(ACMG) for variant classification and reporting [14]. These guidelines classify variants into
five categories: pathogenic, likely pathogenic, variant of unknown significance (VUS), likely
benign and benign. The ACMG criteria for variant classification are based on a set of different
evaluation fields. Population data was determined from public genomic databases (1000
Genomes Project, GnomAD and dbSNP). Other criteria to consider were based on the type of
variant (eg. frameshift, nonsense and essential splice variants) and on clinical, functional and
genotype-phenotype data from the literature and disease databases (Human Gene Mutation
Database Professional, PubMed). If such variants had not been reported previously, they were
evaluated to predict their possible functional significance using in silico prediction tools such
as SIFT (http://sift.jcvi.org/), PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/), PROVEAN
(http://provean.jcvi.org/index.php), Mutation Taster (http://www.mutationtaster.org/), Pan-
ther (http://pantherdb.org/tools/csnpScoreForm.jsp), MutPred2 (http://mutpred.mutdb.org/)
and SNPs&GO (https://snps-and-go.biocomp.unibo.it/snps-and-go/). Rare variants were con-
sidered to be a VUS if the available information had limited or contradictory evidence for
pathogenicity.
MLPA analysis. Patients without pathogenic variants detected by NGS were analyzed by
Multiplex Ligation-dependent Probe Amplification (MLPA) to identify partial and whole gene
deletions or duplications of GCK, HNF1A, HNF4A and HNF1B genes, using the SALSA MLPA
MODY P241 Kit (MRC-Holland, Amsterdam, The Netherlands) according to the manufactur-
er’s instructions. Fragments were separated by capillary electrophoresis (ABI 3130xl Genetic
Analyzer) and analyzed using Gene-Mapper, v.4.0 software (Thermo Fisher Scientific).
Statistical analysis
Statistical analysis was carried out using SPSS software (v.21; SPSS Inc., Chicago, IL). Quanti-
tative variables were expressed as means and standard deviations and qualitative variables as
frequencies and percentages. The Mann-Whitney U test was used to compare quantitative var-
iables. Frequencies were compared using Pearson´s chi-square analysis and Fisher’s exact test
when necessary. The significance level was defined as p< 0.05.
Results
Immunological data
As shown in Table 3, prevalence of GADA, IA2A, IAA and ZnT8A in the 400 new onset pedi-
atric T1D patients was 73.3, 67.3, 64.8 and 57.3%, respectively. In 94.3% of the patients an
autoimmune response against the pancreatic β-cells was detected and 82.8% of them had two
or more positive antibodies. ZnT8A testing increased the number of autoantibody-positive
patients from 373 (93.3%) to 377 (94.3%) and allowed us to diagnose T1D in 14.8% (4/27) of
pediatric patients who were negative for the rest of the antibodies tested. Finally, 23 pediatric
patients (23/400, 5.7%) with clinical T1D diagnosis had negative autoimmunity.
Clinical data and HLA-DRB1 typing
The frequency of ketoacidosis at diagnosis was higher in patients with positive autoimmunity
compared with patients who did not show autoimmunity (40.6% vs. 18.2%, p = 0.036). There
were no significant differences in the age at diagnosis, the family history of diabetes and the
presence of HLA-DRB1 risk alleles for T1D between these two groups of patients (Table 1).
The clinical characteristics and HLA-DRB1 typing of the 23 autoimmune negative patients
are detailed in Table 2. In these 23 patients the mean onset age was 9.6 ± 4.2 years and 34.8%
were female. At the time of diagnosis, the mean BMI z-score was 0.02 ± 1.24, only two patients
MODY in children diagnosed with type 1 diabetes
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had obesity. All patients had hyperglycemia with a low mean C-peptide value of 0.28 ± 0.22
nmol/l and symptoms of diabetes at disease onset lasting from 3 days to 6 months. However,
ketoacidosis was identified at clinical presentation in only 18.2% (4/22) of them. HLA-DRB1
risk alleles for T1D were absent in two patients and the rest had 1 or 2 risk alleles.
Genetic data
A customized panel of 12 MODY genes was tested in 23 patients with negative autoimmunity.
The genetic screening revealed a total of five different rare variants (MAF < 0.01) in 6 patients;
all variants were present in a heterozygous state (Table 4). Two of them were classified as path-
ogenic, representing 8% (2/23) of pediatric patients with suspected T1D and negative autoim-
munity. No partial or whole gene deletions or duplications were detected.
We also performed the genetic study in the 4 patients with only ZnT8A positive autoimmu-
nity. None of them were found to have any variant suspected of monogenic diabetes.
The p.Gly32Ser pathogenic variant in the INS gene (patient 11) is known to cause proinsu-
lin misfolding [15] and has been previously reported in patients with permanent neonatal dia-
betes [16] and also in patients with diabetes onset during infancy, childhood or adulthood
[17–19]. Parental samples were unavailable for genetic analysis. We also identified a novel
pathogenic variant (p.Val264fs) in the HNF1A gene (patient 18) that, as far as we know, has
not been published. This variant involves the thymine duplication at nucleotide 789, resulting
in a frameshift that generates a premature stop codon at position 53 of the new reading frame.
Thus, it is expected to result in a truncated protein with loss of normal function. The variant
co-segregates with early-onset diabetes in the relatives of this family. It was identified in the
younger brother of the proband who had been diagnosed later with diabetes at the age of 10
Table 3. Patients with positive autoimmunity according to the number of antibodies evaluated.
1 antibody Patients with positive autoinmmunity %
ZnT8A 229 57.3
IAA 259 64.8
IA2A 269 67.3
GADA 293 73.3
2 antibodies
IA2A, ZnT8A 316 79.0
IAA, IA2A 333 83.3
IAA, ZnT8A 337 84.3
GADA, ZnT8A 338 84.5
GADA, IAA 351 87.8
GADA, IA2A 361 90.3
3 antibodies
IAA, IA2A, ZnT8A 352 88.0
GADA, IA2A, ZnT8A 367 91.8
GADA, IAA, ZnT8A 370 92.5
GADA, IAA, IA2A 373 93.3
4 antibodies
GADA, IA2A, IAA, ZnT8A 377 94.3
In all patients (n = 400) IAA, GADA, IA2A and ZnT8A were analyzed at diagnosis. Data shows the results of the
different combinations of one or more antibody detection assays. It is considered positive autoimmunity to have at
least one antibody-positive.
https://doi.org/10.1371/journal.pone.0220634.t003
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years. His mother, who was diagnosed primarily with gestational diabetes and subsequently
with diabetes, also carries the same variant.
In our cohort, three other rare variants were found. One VUS variant in the HNF1B gene
(p.His336Asp) was found in patient 14. Parental samples were unavailable for genetic analysis
and there is no information about extra-pancreatic complications. Additionally, in silico analy-
ses were inconsistent. Two other rare variants have recently been re-classified as likely benign
variants. The p.Gly31Asp variant in the HNF1A gene was found in patient 17. Parental analysis
revealed that the variant is carried by her asymptomatic mother and in silico analysis predicted
contradictory results. Finally, the p.Gly76Cys variant in the HNF1B gene is carried by patients
9 and 22. In both cases the variant was inherited from asymptomatic parents who had no
apparent extra-pancreatic complications associated with HNF1B. All the in silico algorithms
predicted a deleterious impact.
Discussion
Different studies of newly diagnosed T1D patients indicate that 6–18% of children and adoles-
cents with clinical T1D do not show evidence of humoral islet autoimmunity at disease onset
[4,32,33]. Our study, with 6% (23/400) of pediatric patients with clinical diagnosis of T1D and
undetectable autoimmunity, corroborates these results.
The molecular genetic screening performed in these autoimmune negative patients showed
five different rare variants. At least two of them are clearly pathogenic alterations responsible
for monogenic diabetes: p.Gly32Ser in the INS gene and p.Val264fs in the HNF1A gene. Con-
sequently, monogenic diabetes was identified in at least 8% (2/23) of pediatric patients with
suspected T1D and negative autoimmunity. Other studies with different approaches, have esti-
mated a prevalence comparable to that of our cohort [34–37]. Furthermore, our study provides
additional evidence that pathogenic variants in INS and HNF genes play critical roles in child-
hood-onset patients with antibody-negative but insulin-requiring diabetes. We did not find
any pathogenic variant in the GCK gene despite its major role in MODY. It is not a surprising
result because heterozygous GCK pathogenic variants result in moderate diabetes that does
not match the typical clinical features of T1D onset on which our study is focused.
In the HNF1A-MODY case (p.Val264fs), three family members carried the same patho-
genic variant, the proband, his mother and the younger brother. The genetic finding allowed
Table 4. Rare genetic variants in MD genes identified in patients with suspected T1D and negative
autoimmunity.
Patient
ID
Gene Exon Nucleotide
change
AA change Type dbSNP MAF_ALL
GnomADe
Variant
effect
Ref.
11 INS 2 c.94G>A p.Gly32Ser Missense rs80356664 0 Pathogenic [15–
19]
18 HNF1A 4 c.789dupT p.Val264fs Frameshift None 0 Pathogenic
14 HNF1B 4 c.1006C>G p.
His336Asp
Missense rs138986885 0.0002 VUS [20–
22]
17 HNF1A 1 c.92G>A p.
Gly31Asp
Missense rs137853247 0.001 Likely
benign
[23–
27]
9 & 22 HNF1B 1 c.226G>T p.
Gly76Cys
Missense rs144425830 0.001 Likely
benign
[27–
31]
Reference sequences: INS, NM_000207.2; HNF1A, NM_000545.5; HNF1B, NM_000458.2. dbSNP: Single Nucleotide
Polymorphism Database. MAF_ALL in GnomADe: Maximum Allele Frequency of the variant in the Exome Genome
Aggregation Database. VUS: Variant of Uncertain Significance
https://doi.org/10.1371/journal.pone.0220634.t004
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us to adjust the treatment of the mother with oral anti-diabetic agents and to prescribe sulfo-
nylureas for the younger brother from the onset of the disease. We simultaneously changed
the treatment of the proband from insulin to sulfonylureas. Mother and younger brother dem-
onstrated a successful response to sulfonylureas. Due to the non-compliance with therapy, the
proband exhibited unstable diabetes control.
Regarding the p.His336Asp variant in the HNF1B gene, it is unclear if it is pathogenic.
Published data do not show clear evidence of pathogenicity [20,21] and it has been classified
as a variant of uncertain significance in a recent report [22]. The other two rare variants, p.
Gly31Asp in the HNF1A gene and p.Gly76Cys in the HNF1B gene, have been recently re-clas-
sified as likely benign polymorphisms [27]. Although the p.Gly31Asp variant has been previ-
ously described in the literature associated with monogenic diabetes [23], the pathogenicity of
this variant is currently questioned based on allele frequency data in the general European
population [24,25] and on functional studies that do not demonstrate a clear impairment of
protein functionality [26]. In addition, the family study shows the variant is inherited from an
unaffected mother. Therefore, based on this information, we interpret p.Gly31Asp as a likely
benign variant. The situation is similar concerning the p.Gly76Cys variant in the HNF1B gene
which, although previously described in the literature associated with monogenic diabetes
[28], has been recently found at a frequency of 0.5% in a healthy Spanish population [29] and
greater than 8% in the North African population [30,31]. This allele frequency is higher than
that expected based on the estimated prevalence of monogenic diabetes in the population.
Moreover, the family study shows that unaffected relatives carry the variant, so based on this
information we interpret p.Gly76Cys as a likely benign variant.
The clinical and analytical data of the patients with non-autoimmune diabetes in our cohort
support the diagnosis of T1D and, except for the absence of autoantibodies, do not specifically
suggest monogenic diabetes. Low fasting serum C-peptide values at the onset of the disease
(less than 0.2 nmol/l) denote low endogenous insulin production and correlate with T1D [38].
In our cohort, 55% (11/20) of the children with negative autoimmunity had low C-peptide lev-
els in conjunction with hyperglycemia at diagnosis. The presence of slightly higher levels in
the rest of the patients might be related to a greater pancreatic reserve at the onset of the dis-
ease. On the other hand, there are only two patients with obesity (patient 2 and 8) who might
be suspected of having T2D. However the likelihood of T2D has been discarded as it is a rare
disease in pediatrics in Europe [39,40]. In addition, both cases are Caucasian, with healthy
parents, clear symptoms of diabetes at diagnosis, not too high C-peptide levels and no clinical
or analytical evidence of insulin resistance. Furthermore, one of them has autoimmune thy-
roiditis. Therefore, although the absence of positive pancreatic-autoantibodies suggests mono-
genic diabetes, a diagnosis of T1D in our cohort should not be definitively ruled out. There
could be other autoantibodies, still not identified, that could have contributed to the develop-
ment of the autoimmune process in these patients and that could be signaled by positivity to
islet cell antibodies (ICA) [32,41]. Additionally, some mildly positive cases could not be identi-
fied by the assays. This error is minimized in our study by the combined measurement of four
pancreatic-antibodies for the diagnosis, achieving a 94.3% autoimmunity detection rate at the
onset of the disease.
In our cohort, the addition of the ZnT8A test to the traditional set of diabetes associated
autoantibodies has made it possible to identify autoimmunity in four patients who were
ZnT8A positive and otherwise antibody-negative. This represents a non-negligible percentage,
close to 15% of patients (4/27), who were diagnosed properly as T1D. The absence of patho-
genic variants in the four patients with only ZnT8A positive, supports recently published data
confirming ZnT8A as a marker for excluding patients from genetic testing for monogenic dia-
betes [42,43].
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Although autoantibodies are so far considered as the best biomarker to discriminate
MODY from T1D, we cannot ensure that there is no monogenic diabetes among pediatric
patients with positive autoimmunity at diagnosis. Nevertheless, both in our experience [11]
and in previously published studies [44,45], the proportion of patients with positive autoim-
munity and molecular diagnosis of MODY is the same as expected in the control population,
suggesting that autoantibodies are rare in MODY. However, other studies with different
approaches show higher prevalence of positive autoantibodies among MODY cases. GADA
and IA2A were found in Czech patients with MODY and delayed diabetes onset with insuffi-
cient disease control [46]. Pancreatic autoantibodies were also found in a high proportion
(17%) in German and Austrian patients with MODY, but this might be an overestimation due
to the fact that the diagnosis of MODY was not confirmed by genetic testing in 20% of studied
patients. Surprisingly, using the same testing protocol, the positive rate in patients with type 2
diabetes was even greater than in MODY patients [47].
A significantly lower presence of ketoacidosis at diagnosis in autoimmune negative patients
was found in our cohort, reflecting a less aggressive onset of diabetes in this subset of patients.
Nevertheless, factors involved in DKA development are not yet clear. A recent report has
found a correlation between the number of positive antibodies and the severity of ketoacidosis
[48], which supports the relation of DKA to the intensity of destruction of pancreatic β-cells.
Other reports have found a greater risk of DKA associated with different specific antibodies
[48,49]. However, most of the published data find no difference in rates of DKA and presence
or absence of autoimmunity [50,51] which substantiates the relationship of DKA to delayed
diagnosis rather than to the expression of antigenicity. Our study did not have the capacity to
find any other clinical differences among patients with positive and negative autoimmunity
and carriers and non-carriers of pathogenic variants, probably due to the small number of
patients. The two probands carrying pathogenic variants in this study had been previously
diagnosed with T1D, despite the absence of autoimmunity. In these particular cases, neither
clinical data nor HLA-DRB1 helped to differentiate MODY. In fact, both patients with MODY
had HLA-DRB1 risk alleles for T1D (1 and 2 risk alleles). Furthermore, as the presence of two
HLA-DRB1 risk alleles for T1D increases the probability of developing autoimmune diabetes
[11] we cannot dismiss the possibility that the proband carrying two HLA-DRB1 risk alleles
may also develop autoimmune diabetes in the future.
The main strength of the current study is the well-characterized cohort of T1D patients
based on the combination of four autoantibody assays. This enabled us to accurately define the
antibody-negative patients who were the target of the molecular testing. Another advantage is
the screening approach by NGS that extends the search for genetic variants to twelve genes
related to MD as well as the MLPA analysis. The possibility of misdiagnosing patients with
rarer forms of monogenic diabetes cannot be completely excluded, as patients may carry
variants in other known MD genes not tested in this study or in a gene not yet identified as a
monogenic cause of diabetes.
In summary, our study shows that ZnT8A is an autoantibody to be considered for improv-
ing the diagnosis of T1D in pediatrics. In addition, at least 8% of pediatric patients suspected
of T1D but with undetectable autoimmunity have monogenic diabetes and can benefit from
the correct diagnosis of the disease by genetic study.
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